Free Trial
Yun Zhong

Yun Zhong Analyst Performance

Senior Vice President, Equity Research at Wedbush

Yun Zhong is a stock analyst at Wedbush in the medical sector, covering 18 publicly traded companies. Over the past year, Yun Zhong has issued 5 stock ratings, including and buy recommendations. While full access to Yun Zhong's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Yun Zhong's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
30 Last 7 Years
Buy Recommendations
89.66% 26 Buy Ratings
Companies Covered
18 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy89.7%26 ratings
Hold10.3%3 ratings
Sell0.0%0 ratings

Out of 29 total stock ratings issued by Yun Zhong at Wedbush, the majority (89.7%) have been Buy recommendations, followed by 10.3% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
18 companies

Yun Zhong, an analyst at Wedbush, currently covers 18 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
18 companies
100.0%

Yun Zhong of Wedbush specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
9 companies
50.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
3 companies
16.7%
BIOTECHNOLOGY
2 companies
11.1%
MED - DRUGS
2 companies
11.1%
MED - GENERIC DRG
1 company
5.6%
PHARMACEUTICAL PREPARATIONS
1 company
5.6%

About Yun Zhong

Yun Zhong, PhD, is a senior research analyst specializing in biotechnology. Before joining Wedbush, he served as a vice president on the biotech team at Jefferies and held senior biotech analyst roles at Janney Montgomery Scott, Berenberg Capital Markets, and BTIG. Yun's expertise spans orphan diseases, genetic medicine, hematology, neuromuscular diseases, and metabolic disorders. His career began at Cowen and Company, followed by a position at SunTrust Robinson Humphrey. Yun earned his PhD in neuroscience and molecular biology from Rockefeller University and holds both an MS and a BS in biophysical engineering from Osaka University in Japan. His strong technical background and genuine interest in the scientific aspects of biotechnology allow him to understand therapeutic mechanisms at a molecular level, providing a more objective and differentiated perspective. Yun is particularly focused on gene therapy and genetic medicine, areas where he remains optimistic about its potential to offer significant advancements in patient care.
Follow on LinkedIn

Yun Zhong's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Passage Bio, Inc. stock logo
PASG
Passage Bio
8/13/2025Boost Price Target$5.97$40.00Outperform
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
8/11/2025Initiated Coverage$8.73$28.00Outperform
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/8/2025Boost Price Target$183.33$220.00Outperform
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
8/7/2025Lower Price Target$3.40$8.00Outperform
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
5/27/2025Initiated Coverage$2.01$8.00Outperform